Saltar al contenido
Merck
  • Synergistic combinations of tanshinone IIA and trans-resveratrol toward cisplatin-comparable cytotoxicity in HepG2 human hepatocellular carcinoma cells.

Synergistic combinations of tanshinone IIA and trans-resveratrol toward cisplatin-comparable cytotoxicity in HepG2 human hepatocellular carcinoma cells.

Anticancer research (2014-10-03)
Tung-Wu Chang, Chueh-Yu Lin, Yin-Jeh Tzeng, Huu-Sheng Lur
RESUMEN

To determine the combinative effects of tanshinone IIA (Tan IIA) and trans-resveratrol (Resv) on cytotoxicity, apoptosis, cell-cycle arrest and DNA fragmentation in HepG2 human liver cancer cells. Cytotoxicity was detected by the cell proliferation and cytotoxicity WST-1 assay. Cell-cycle arrest and apoptosis were determined using flow cytometry analysis. DNA fragments were separated by gel electrophoresis. Tan IIA and Resv at mixture ratios of 1/2:1/2 and 1/3:2/3 exerted synergistic cytotoxicity comparable to that of cisplatin. Elevated proportions of sub-G1 and apoptotic cells were respectively found in the combinative treatments in comparison with hypothetic values of additive effects. Moreover, a more intensive pattern of apoptotic DNA fragmentation was visualized in combined treatments than in individual ones. Combining Tan IIA and Resv causes synergistic cisplatin-comparable, cytotoxicity and robustly induces apoptosis, sub-G1 cell cycle arrest and DNA fragmentation. This study provides evidence supporting further pre-clinical investigations of the combinational synergism.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Resveratrol, ≥99% (HPLC)
Supelco
Resveratrol, analytical standard
Sigma-Aldrich
Tanshinone IIA, ≥97% (HPLC)
Supelco
Resveratrol, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Tanshinone I, ≥98% (HPLC)
Resveratrol, European Pharmacopoeia (EP) Reference Standard
Tanshinone IIA, European Pharmacopoeia (EP) Reference Standard